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Anunresolveddebate inAlzheimer’s disease (AD) iswhether amyloidplaques arepathogenic, causingovert physical disruptionof neural
circuits, or protective, sequestering soluble forms of amyloid- (A) that initiate synaptic damage and cognitive decline. Few animal
models of AD have been capable of isolating the relative contribution made by soluble and insoluble forms of A to the behavioral
symptoms andbiochemical consequences of the disease.Hereweuse a controllable transgenicmousemodel expressing amutant formof
amyloid precursor protein (APP) to distinguish the impact of soluble A from that of deposited amyloid on cognitive function and
synaptic structure. Rapid inhibition of transgenic APPmodulated the production of Awithout affecting pre-existing amyloid deposits
and restored cognitive performance to the level of healthy controls in Morris water maze, radial arm water maze, and fear conditioning.
Selective reduction of A with a -secretase inhibitor provided similar improvement, suggesting that transgene suppression restored
cognition, at least in part by lowering A. Cognitive improvement coincided with reduced levels of synaptotoxic A oligomers, greater
synaptic density surrounding amyloid plaques, and increased expression of presynaptic and postsynaptic markers. Together these
findings indicate that transient A species underlie much of the cognitive and synaptic deficits observed in this model and demonstrate
that significant functional and structural recovery can be attained without removing deposited amyloid.
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Introduction
Amyloid- (A) peptides produced by the cleavage of the amy-
loid precursor protein (APP) are a major focus of drug develop-
ment for Alzheimer’s disease (AD). However, there is little
consensus about what form of A–monomer, small soluble as-
semblies, or aggregated deposits–should be targeted therapeuti-
cally. Initial testing in animal models suggested that cognitive
protection could be achieved by lowering all forms of A by
preventative active immunization (Janus et al., 2000; Morgan et
al., 2000), while subsequent studies using passive immunization
or -secretase inhibitors (GSIs) suggested that decreasing soluble
A and oligomeric assemblies was sufficient to restore cognitive
function (Dodart et al., 2002; Kotilinek et al., 2002; Comery et al.,
2005; Lee et al., 2006). However, many of these studies either
tested before amyloid formation (Martone et al., 2009; Fuku-
moto et al., 2010; Balducci et al., 2011;Mitani et al., 2012; Zago et
al., 2012), or used chronic treatments that affected plaque burden
(Wilcock et al., 2004, 2006; Hartman et al., 2005; Chang et al.,
2011). To date, only a limited number of studies have sought to
distinguish the contribution made by different pools of A to
cognitive impairments in mouse models of AD (Dodart et al.,
2002; Comery et al., 2005; Lee et al., 2006; Melnikova et al., 2013;
Mitani et al., 2013). However, most of these studies relied on a
single behavioral measure to evaluate cognitive efficacy, and
none examined recovery at the level of neuronal structure or
function.
Both soluble and insoluble forms ofA can dramatically affect
neuronal structure and function. Axons passing near amyloid
plaques develop large distended swellings of ubiquitinated aggre-
gates separated by domains that are abnormally thin and tortu-
ous (Le et al., 2001; D’Amore et al., 2003; Stokin et al., 2005). In
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addition to these gross morphological changes in neighboring
neurons, amyloid formation is associated with alterations in both
local and long-distance neuronal signaling. Amyloid-bearing an-
imals show diminished signal transmission between hemispheres
with reduced response precision (Stern et al., 2004). Subsets of
neurons in the vicinity of fibrillar deposits become hyperactive,
while neighboring astrocytes develop spontaneous calciumwaves
uncoupled from local network activity (Busche et al., 2008;
Kuchibhotla et al., 2008, 2009). The physical response to soluble
oligomeric A is considerably more subtle than the reaction to
insoluble deposits, although no less consequential. Mounting ev-
idence suggests that oligomeric A in forms ranging from dimers
and trimers to larger oligomers and protofibrils can be potently
synaptotoxic (Wilcox et al., 2011; Larson and Lesne, 2012). In
vitro application of naturally secreted oligomeric preparations
causes rapid loss of dendritic spines and deficits in synaptic plas-
ticity, while intracranial injection of similar preparations impairs
learning and memory (Wilcox et al., 2011; Larson and Lesne,
2012). Together, these studies suggest a complex relationship be-
tween soluble and insoluble forms of A, alterations in neuronal
structure and function, and resulting cognitive decline.
We sought to dissect this relationship using a unique mouse
model in which the expression of transgenic APP and consequent
overproduction of A could be arrested by treatment with doxy-
cycline (dox). In past work, we have shown that suppressing
transgenic APP expression after amyloid onset stops further
plaque deposition while having little effect on pre-existing amy-
loid (Jankowsky et al., 2005; Wang et al., 2011). Here, we use this
system to test the potential for synaptic and cognitive recovery
following acute reduction of transgenic APP/A in the continued
presence of amyloid plaques. Bymodulating the levels of APP and
soluble A independently from amyloid load, we demonstrate
significant functional and structural restoration, suggesting that
substantial therapeutic benefit may be possible by reducing fur-




The tet-responsive APP transgenic line 102 (tetO-APPswe/ind 102;
MMRRC stock # 034845-JAX; Jankowsky et al., 2005) and the tet-
activator line B CaMKII-tTA (Jackson Laboratories #3010; Mayford et
al., 1996) were independently backcrossed to C57BL/6J for25 genera-
tions before being intercrossed for these studies. The resulting double
transgenicmale offspringwere thenmatedwithwild-type FVB females to
produce experimental cohorts on a FVBB6 F1 background.
Dox administration. All mice used in this study were raised on dox to
suppress transgene expression during postnatal development. We have
previously shown this strategy to ameliorate locomotor hyperactivity and
normalize body weight of double transgenic animals, permitting reliable
cognitive testing (Rodgers et al., 2012).Offspringwere started ondox 1–3
d after birth by placing nursingmothers onmedicated chow, formulated
to 50 mg/kg dox (Purina Mills TestDiet #5APL). At weaning, mice were
maintained on dox until 6 weeks of age (Purina Mills TestDiet #5SBA).
All mice were returned to regular chow for the following 6 months,
allowing APP/tetracycline transactivator (TTA) animals to develop a
moderate amyloid load. To test the potential cognitive benefit of short-
term APP suppression, at 7.5 months half of the mice were treated with
dox for 2 weeks before behavioral testing and were maintained on dox
until harvest.
During the course of this study, we discovered that the lot of chow we
had purchased for postnatal treatment provided submaximal transgene
suppression (80% suppression rather than the 90–95% we expected at
this dose), so therapeutic administration at 7.5 months was done by
administering dox in the drinking water at a dose of 50 g/ml supple-
mented with 5% sucrose to mask the bitter taste.
GSI administration. A separate cohort of age-matched mice that had
also expressed transgenic APP for 6 months was treated with GSI to
confirm that behavioral recovery attained by transgene suppression with
dox was due to reduction of A. LY411575 was administered either in
drinkingwater at a concentration of 40g/ml (GSI stock dissolved at 100
mg/ml in DMSO/ethanol to yield a working solution containing 1%
DMSO and 0.8% ethanol) or through the chow at a concentration of 25
mg/kg (BioServ Rodent Diet #156166), in both cases to deliver an esti-
mated dose of 5 mg/kg/d. Behavioral analysis began 5 d after treatment
started.
Behavioral assays
Behavioral testing began at 8 months of age and included open field,
Morris water maze (MWM), radial arm water maze (RAWM), and con-
textual fear conditioning (CFC). Animals were handled for 3 d before the
start of behavioral testing. Locomotor activity was assessed on day 1,
followed by MWM training on days 2–10, and RAWM training on day
11. Mice were allowed a 2 d rest period before fear conditioning training
on day 14, which was followed by a retention test 24 h later. All animal
experiments were reviewed and approved by the Baylor College of Med-
icine Institutional Care and Use Committee.
Open-field assessment. Locomotor activity was assessed inwhite acrylic
open-top boxes (46 46 38 cm) in a room lit by indirect white light.
Activity was recorded for 30 min and analyzed using the ANY-maze
Video Tracking System (Stoelting).
MWM.MWM testing was conducted in a circular tank measuring 58
cm high and 122 cm in diameter. The water level was 20 cm from the top
of the tank andmade opaque using nontoxic white paint. Water temper-
ature was maintained between 21 and 23°C. The room was lit with indi-
rect white light and trials were recorded and tracked using ANY-maze
Video Tracking System.
Before the start of acquisition training, mice received 1 d of training in
a straight swim channel to acclimate them to the water and check for
motor deficits. Mice received eight trials with a 15 min intertrial interval
(ITI) in a channel constructed of white acrylic and measuring 107 56
14 cm, which was placed in the center of pool. Visible cues were re-
moved from the room during straight swim shaping trials. Mice were
allowed 60 s to reach a submerged platform on the opposite side of the
channel. Mice that failed to reach the platform were guided to the loca-
tion by the experimenter. Mice were allowed to stay on the platform for
15 s before being removed from the water, dried, and returned to their
home cage under an infrared lamp between trials.
Acquisition training in the MWM consisted of four trials per day with
a 15 min ITI. Each training session ended with a short-term memory
probe. A square platform (10 10 cm) covered in nylon mesh for trac-
tion was located 1 cm below the surface in the NE quadrant of the maze,
half way between the side and the center of the pool. Mice were placed in
the maze facing the wall at each of four cardinal start locations and
allowed 60 s to locate the hidden platform.Aswith straight swim, animals
that failed to locate the platform in the allotted time were gently guided
there by the experimenter. Mice were allowed to stay on the platform for
15 s before being returned to their home cage between trials. Following
the 4 training trials, the platform was removed from the maze for an
immediate probe trial. Animals were placed in the tank half way between
the cardinal points (SW, NW, SE, and NE) and allowed 45 s to navigate
the maze. Proximity to target, percentage time, and percentage path
spent in each quadrant were calculated along with the number of times
the animal crossed the platform location compared with the other three
potential platform locations (in the SW, NW, and SE quadrants). Mice
were trained to a performance criterion during probe trials of35%path
in the correct quadrant and at least 40% of total platform crossings over
the correct site compared with other possible platform locations.
When mice reached criterion, they were retired from further MWM
training, but given a final long-term memory probe 24 h after reaching
criterion. Mice were trained for a maximum of 7 d. After all mice either
reached criterion or completed 7 d of training, each was given one addi-
tional “refresher” day of training (four trials) with probe test to ensure
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equivalent performance between groups before starting RAWMtraining.
During this refresher training, performance in our cohorts was identical
both between genotypes (F(2,52) 0.34, p 0.05) and treatment groups
(F(1,52) 0.74, p 0.05). Thus, this procedure ensured that allmice were
trained to a similar performance level before moving onto RAWM test-
ing in the same room.
RAWM.The day followingMWMrefresher training,mice received 1 d
of RAWM training consisting of eight trials with a 15 min ITI. The
RAWMwas created by installing clear Plexiglas triangular inserts into the
existing water maze pool (41.25 cm on each side  50 cm high), which
resulted in six open arms joined at the center. Each armmeasured 20 cm
wide  34 cm long, and the water was maintained at a depth of 38 cm.
The platform was located 3 cm from the end of one arm and submerged
1 cm below the water’s surface. Mice were placed into a different arm at
the beginning of each trial, with the order of starting positions pseudo-
randomly selected before training such that no trial began in an arm
adjacent to the previous start position.Micewere allowed 60 s to navigate
the maze. If a mouse failed to locate the platform in the allotted time, it
was gently guided to there by the experimenter and allowed to remain on
the platform for 15 s before being returned to its home cage between
trials. Latency to locate the platform, swim path length, and number of
working memory errors (re-entries into a previously visited arm) were
calculated for each trial. Trial 1 scores were excluded from analysis due to
the inflated error rate as animals learned the new procedure. Data from
trials 2–8 was averaged to provide a performance index for overall
RAWM learning. After the final training trial, animals were tested with a
short-term probe trial in which the platform was removed and animals
were allowed 45 s to navigate themaze. Percentage time and path spent in
the target arm were calculated and compared among treatment groups.
CFC. Two days after RAWM testing, mice were trained in CFC using a
near-infrared video fear conditioning system (Med Associates). Condi-
tioning boxes (30.5 24 21 cm) with a stainless steel grid floor were
located inside sound-attenuating chambers and indirectly lit from above.
Movement was recorded by a video camera mounted inside the sound-
attenuating chamber and analyzed using Video Freeze software (Med
Associates). Motion threshold was set to 19 arbitrary units (a.u.) and the
minimum freeze duration to 1 s. Chambers and grid floors were cleaned
with a 20% ethanol solution after each trial.
During conditioning, mice were allowed to freely explore the cham-
bers for 2 min before receiving a 1 s 0.8 mA footshock. After a 2 min
interval, mice received a second 1 s 0.8 mA footshock. Mice remained in
the chamber for 1 min after second footshock before being returned to
their home cage. Twenty-four hours later, animals were returned to the
same conditioning box for a 5min retention test. The duration of immo-
bility was recorded and used as an index of learning.
Tissue harvest
One week after behavioral testing was completed, mice were killed by
sodiumpentobarbital overdose and transcardially perfused with ice-cold
PBS containing 10 g/ml heparin. Brains were removed and hemisected
along themidline.One hemispherewas dissected to isolate the cortex and
hippocampus, which were snap frozen for biochemistry, and the other
hemisphere was immersion fixed in 4% PFA at 4°C for 48 h. Brains were
cryoprotected in 30% sucrose at 4°C. Tissue was sectioned at 35 m in
the sagittal plane using a freezing slidingmicrotome, then stored in cryo-
protectant (0.1 M phosphate buffer, pH 7.4, 30% ethylene glycol, and
25% glycerol) at20°C until use.
Histology
Campbell–Switzersilverstain.Adetailedprotocolforthisstaincanbefoundatthe
NeuroScience Associates website (http://www.neuroscienceassociates.com/
Documents/Publications/campbell-switzer_protocol.htm).
Thioflavine-S histology. A 1/12 series of sections spaced at 420 m
intervals were stained for thioflavine. Sagittal 35msectionswere rinsed,
mounted onto SuperFrost Plus slides, and dried overnight. Sections were
rehydrated in running tap water, incubated for 10–15 min in 0.25%
potassiumpermanganate, followed by 5min in 1%potassiummetabisul-
fite/1% oxalic acid, before staining in 0.02% thioflavine-S (Sigma
#T1892) for 8 min. Staining was differentiated in 80% ethanol, followed
by running tap water. Sections were dehydrated through xylene and
coverslipped with Permount.
Synaptophysin immunofluorescence and thioflavine-S histology. A 1/24
series of sections spaced at 840 m intervals were immunostained for
synaptophysin and counterstained for thioflavine. Sagittal 35 m sec-
tions were rinsed, blocked in TBS plus 0.3% Triton X-100 (TBST) and
5% normal goat serum for 1 h at room temperature, and stained with
rabbit anti-synaptophysin antibody (#AB9272;Millipore) diluted 1:1000
in blocking solution overnight at 4°C. Sections were then washed with
TBS and incubated with Alexa 568-conjugated secondary antibody (goat
anti-rabbit IgG #A11011; Invitrogen) diluted 1:500 in block at room
temperature for 1 h. Sections were washed with TBS before being coun-
terstained with 0.002% thioflavine-S (#T1892; Sigma) diluted in TBS at
room temperature for 8 min. After two 1 min washes in 50% ethanol
followed by several washes in TBS, sections weremounted on SuperFrost
Plus slides and coverslippedwithVectashieldmountingmedium (Vector
Laboratories).
A immunohistochemistry. A 1/12 series of sections spaced at 420 m
intervals were rinsed with TBS, pretreated with 88% formic acid for 1
min at room temperature, and blockedwithTBST containing 5%normal
goat serum before overnight incubation at 4°C with rabbit anti-human
A antibody (#71-5800; Zymed/Invitrogen) diluted 1:500 in blocking
solution. After several washes in TBS, sections were incubated with
biotin-conjugated goat anti-rabbit secondary (Vectastain Elite ABC Kit,
Rabbit IgG; Vector Laboratories) diluted 1:500 in blocking solution for
1 h at room temperature followed by HRP-avidin conjugate diluted 1:50
in TBS for 30 min at room temperature. Sections were developed with
DAB (#D4418; Sigma), then mounted, dehydrated, and coverslipped
with Permount.
Quantification of amyloid burden. Amyloid burden was quantified us-
ing a custom macro written for Zeiss AxioVision 4.8 software as de-
scribed previously (Wang et al., 2011). Color thresholds were used to
identify amyloid plaques in high-resolution digital scans of A immuno-
stained and thioflavine-S stained sections using a custom macro written
with Zeiss AxioVision software. Background staining and shading arti-
facts were manually excluded from the analyses. The region of interest
was specified by outlining the cortex or hippocampus and the area above
threshold computed relative to total area. Three (A immunostain) or
six sections (thioflavine-S) spaced at 420m intervals weremeasured for
each animal.
Quantification of synaptophysin. The area of synaptophysin immuno-
staining surrounding thioflavine-S-positive fibrillar plaques was mea-
sured using a custom script written in MATLAB (R2012b) to batch
process two-channel fluorescence images in an unbiased and automated
way. Two tissue sections spanning the frontal cortex were selected for
analysis from each animal. Two nonoverlapping fields of view each
centered on an isolated plaque of 43.56 m average diameter were
photographed for each section. A single optical plane of 0.98 m in
depth was collected from each field in the red (synaptophysin) and
green (thioflavine) channels using an ApoTome structured illumina-
tion device (Carl Zeiss). At 40 magnification each field spanned an
area of 222.2  166.4 m.
The first step in the automated script removed the area occupied by the
thioflavine-positive plaque from the region of interest that would be used
be used to measure synaptophysin. To accomplish this in an unbiased
fashion, we binarized the grayscale thioflavine images using Otsu’s
method. TheOtsumethodworks by calculating the threshold at which to
divide the dataset into signal and background so that the variance in each
of the resulting subsets is minimized. In this case, the method uses vari-
ance minimization to define the cutoff between thioflavine-positive pix-
els and thioflavine-negative pixels. Pixels above background defined the
area of the plaque andwere used as amask to remove this region from the
corresponding synaptophysin image. Themasked synaptophysin images
were then also binarized, again applying Otsu’s method for determining
the optimal threshold between signal and background. The script then
calculated the area occupied by synaptophysin-positive pixels in each
image, normalizing to the total area remaining after the region of thio-
flavine staining was removed. We have posted the script on MATLAB’s




APP, synapsin, and PSD95. Frozen cortical samples were prepared for
Western blotting by sonication in 2% SDS plus 1 protease inhibitor
cocktail (Sigma P8340) and then diluted 1:1 with 2 SDS-free RIPA
buffer (2PBS, 1%deoxycholate, 1%NP40, and 5mMEDTA). For APP,
50 g of the resulting homogenate was separated on a 10.5–14% Tris-
HCl gel (Bio-Rad Criterion) and transferred to nitrocellulose. For syn-
apsin and PSD95, 25 g of cortical homogenate was separated on a
4–15% Tris-HCl gel and transferred to nitrocellulose. Membranes were
blocked in PBS plus 0.1% Tween 20 and 5% nonfat dry milk for 1 h at
room temperature. APP/A antibody 6E10 andPSD95was used to probe
the upper part of the blot; GAPDH was used to probe the lower part as a
loading control. HRP-labeled secondary antibodies [goat anti-mouse
IgG diluted 1:5000 (#115-035-003; Jackson ImmunoResearch) and goat
anti-chicken IgG diluted 1:10,000 (#14-24-06; Kirkegaard & Perry
Laboratories)] were used to detect binding, and developed with Immo-
bilon ECL Reagent (#WBKLS0100; Millipore). Chemiluminescence was
measured with a Fuji miniLAS-4000 system and quantified using Multi-
Gauge software. After imaging, the blot was stripped by incubation for 30
min at 50°C in 50 mM Tris-HCl, 2% SDS, and 0.7% -mercaptoethanol
and the upper portion reprobed for synapsin as above.
ADF/cofilin and PAK1. Frozen cortical samples were prepared for
Western blotting by cellular fractionation described below. Approxi-
mately 50 g of the intracellular fraction was separated on a 4–15%
Tris-HCl gel and transferred to nitrocellulose. Phosphorylated cofilin
and PAK1 was probed first using rabbit anti-phospho-cofilin (1:500;
#3311; Cell Signaling Technology) or rabbit anti-phospho-PAK1 (1:
1000; #2601; Cell Signaling Technology) in conjunction with chicken
anti-GAPDH (1:10,000; #AB3202; Millipore) as a loading control. After
chemiluminescence was measured, blots were stripped as described
above and reprobed for total levels of protein using rabbit anti-cofilin
diluted 1:1000 (#5175; Cell Signaling Technology) or rabbit anti-PAK1
(1:1000; #2602; Cell Signaling Technology).
Oligomeric A. Frozen cortical samples were fractionated by a four-
step extraction method. Extraction began by mechanical homogeniza-
tion in 250l of 50mM Tris-HCl, pH 7.6, 0.01%NP-40, 150mMNaCl, 2
mM EDTA, 0.1% SDS, and 1 PPP [1 mM phenylmethylsulfonyl fluo-
ride, 2 mM 1,10-phenanthroline monohydrate, and 1 protease inhibi-
tor cocktail] using five passes through a 1 ml syringe with a 20 gauge
needle. Soluble, extracellular-enriched proteins were collected from the
supernatant of this extract following 10min at 800 g, 4°C. The remain-
ing pellet was then mechanically dissociated by trituration with an Ep-
pendorfmicropipette in 250l of 50mMTris-HCl, pH7.4, 150mMNaCl,
0.1% Triton X-100, and 1 PPP. Cytoplasmic proteins were collected
from the supernatant of this extract following 90 min at 16,100 g, 4°C.
The remaining pellet was then triturated with amicropipette followed by
passive lysis on a rotating platform for 15 min at 4°C in 250 l of 50 mM
Tris-HCl, pH 7.4, 150 mM NaCl, 0.5% Triton X-100, 1 mM EGTA, 3%
SDS, 1% deoxycholate, and 1 PPP. Membrane-enriched proteins were
collected from the supernatant of this extract following 90 min at
16,100  g, 4°C. The membrane-enriched fraction was clarified by 60
min at 100,000 g. Each fraction was depleted of endogenous immuno-
globulins by sequential incubation for 1 h at 4°C with 50 l of protein
A-Sepharose, Fast Flow followed by 50 l of protein G-Sepharose, Fast
Flow (GEHealthcare Life Sciences). All supernatants were clarified by 90
min at 16,100 g before Western blot analysis.
One hundred micrograms of protein per sample was electrophoresed
on 10–20% SDS-polyacrylamide Tris-tricine gels (Bio-Rad). Proteins
were transferred to nitrocellulose and membranes boiled in PBS for 5
min. Membranes were blocked in TBSTw containing 5% bovine serum
albumin (#A3803; Sigma,98%grade) for 2 h at room temperature, and
probed with either 6E10 (#SIG-39320; Covance) or biotinylated-6E10
(#SIG-39340; Covance) diluted 1:2500 in blocking solution. A duplicate
set of gels loaded with 50g or 20g protein was blotted and probed for
-synuclein (extracellular fraction; Covance #SIG-39720 diluted
1:5,000) or actin (membrane fraction; Sigma #A2066 diluted 1:10,000) as
internal controls to demonstrate equal protein concentrations across
samples. Primary antibodies were detected using anti-IgG conjugated
with either biotin or infrared dyes (LI-COR Biosciences). When biotin-
conjugated antibodies were used, DyLight800-conjugated NeutrAvidin
(#22853; Thermo Scientific) was added to amplify the signal. Blots were
imaged with an Odyssey detection system (LI-COR Biosciences). Densi-
tometry analyses were performed using OptiQuant software (Packard
Bioscience) or Image Studio software (LI-COR Biosciences).
Dot blotting
Twomicrograms of extracellular-enriched ormembrane-associated pro-
tein lysates were mixed with sterile filtered deionized water in a total
volume of 2.5 l. Each sample was then adsorbed onto a nitrocellulose
membrane until dry. Following a brief activation in 10%methanol/TBS,
the membrane was boiled in PBS to enhance antigen detection as previ-
ously described (Sherman and Lesne´, 2011).Membranes were blocked in
TBS containing 5% bovine serum albumin for 60 min, then moved to
primary antibody 6E10 (1:2500) and A11 (1:2000; a kind gift from Rakez
Kayed, University of Texas Medical Branch, Galveston, TX) for over-
night incubation at 4°C. Following several washes, anti-mouse IgG-
IR800 (1:100,000) and anti-rabbit IgG-IR680 (1:150,000) secondary
antibodies were used for detection with a Li-Cor Odyssey imager. All
steps were performed without detergent to enhance A11 binding of oli-
gomeric species as previously reported (Lesne´ et al., 2006).
Immunoprecipitation
Two hundred micrograms of protein extract was diluted to 1 ml with
dilution buffer (50 mM Tris-HCl, pH 7.4, and 150 mM NaCl) and incu-
bated with 5 g of 6E10 overnight at 4°C. The following day, 50 l of
Protein G-Sepharose, Fast Flow (GE Life Sciences) was added [mixed 1:1
(v:v) with immunoprecipitation (IP) buffers A and B; Sherman and Le-
sne´, 2011] and incubated at 4°C for 2 h. The beads were washed twice in
1 ml of dilution buffer and proteins were eluted by boiling in 30 l of
SDS-PAGE loading buffer.
In vivo microdialysis.Mice were unilaterally implanted with a 38 kDa
molecular weight cutoffmicrodialysis probe (2mmBR-style; Bioanalyti-
cal Systems) by placing the probe tip into the hippocampus at a 12 degree
angle 3.1 mm from bregma, 2.5 mm from midline, and 3.2 mm
below the dura (Cirrito et al., 2003, 2011).Microdialysis perfusion buffer
consisted of 4% albumin in artificial CSF at a flow rate of 1.0 l/min.
Animals were allowed to recover for 6–8 h after probe insertion, then six
interstitial fluid (ISF) A measurements were taken over a 6 h period.
The mean concentration of exchangeable A during this 6 h period was
defined as the baseline ISF A concentration for eachmouse. After base-
line A levels were established, mice were treated with dox at a concen-
tration of 50 g/ml in their drinking water for 4 d. During this time,
microdialysis samples were continuously collected every 1–3 h into a
refrigerated fraction collector. Following the final collection, samples
were assayed for Ax-40 and Ax-42 by sandwich ELISA using an A40
(mHJ2) or A42-specific antibody (mHJ7.4) to capture the peptide fol-
lowed by a biotinylated central domain anti-A antibody (mHJ5.1) for
detection (Cirrito et al., 2011). The concentration of ISF A in each
sample was normalized to the baseline A concentration for eachmouse.
At the end of the experiment, the brains were harvested and processed for
histological verification of probe placement.
Statistical analysis
Data were analyzed using one-way or two-way ANOVA or t test where
appropriate. All post hoc comparisons were conducted using Bonferroni
correction. Statistical tests for behavioral experiments were conducted
using SPSS Statistics 20 (IBM). Statistical tests for biochemical and his-
tological experiments were conducted using Prism 6.0 (GraphPad).
Graphs were created using Prism 6.0 and display group means SEM.
Results
Dox rapidly suppresses transgenic APP expression, decreases
exchangeable A levels, and stabilizes amyloid load
We studied a temporally controlled transgenic mouse model in
which the TTA activates expression of human APPswe/ind within
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forebrain neurons. In this system, TTA acts as an artificial tran-
scription factor specific for the tetO promoter controlling trans-
genic APP. On administration of dox, TTA undergoes a
conformational change that prevents it from binding DNA and
thereby arrests further expression of transgenic APP (Fig. 1A).
We took advantage of this system to test whether acutely reducing
production of transgenic APP and A is sufficient to rescue cog-
nitive impairments after the onset of amyloid deposition. Be-
cause we have previously shown that APP
overexpression during postnatal develop-
ment causes severe locomotor hyperactiv-
ity (Rodgers et al., 2012), here we used
mice in which transgene expression was
delayed until adulthood (Fig. 1B). Trans-
gene expression was initiated at 6 weeks of
age and continued for an additional 6
months to producemoderate amyloid de-
position in APP/TTA double transgenic
mice by the age of behavioral testing. In
past work we have shown that amyloid
formed during this period of APP overex-
pression persists for 18 months after
transgene suppression (Jankowsky et al.,
2005; Wang et al., 2011; J.L. Jankowsky,
unpublished data).Together, this model
provides a way to controllably arrest fur-
ther production of transgenic APP and
soluble A without affecting pre-existing
amyloid.
We first examined the rate and effi-
ciency of transgenic APP suppression in
the tet-off model using mice of approxi-
mately the same age as our behaviorally
tested animals, but which were killed
within 1–4 d of starting dox treatment.
Western blotting of transgenic APP levels
across days revealed that APP expression
was reduced by 40% within 24 h of dox
treatment and reached 90% suppression
at 48 h (Fig. 2A,B). We confirmed that
APP suppression could be chronically
maintained at this level by measuring
transgenic APP expression in behaviorally
tested animals treated for 5 weeks on dox,
as shown by comparingAPP expression in
mice that were harvested after 5 weeks of
differential treatment (Fig. 2C). These
mice showed the same degree of suppres-
sion as animals harvested after 2 d on dox,
with transgenic APP levels 10% that of
untreated mice (t  102.1, df  8, p 
0.001). These results indicate that APP
suppression had stabilized at 90% be-
fore behavioral testing and remained at
this level throughout our experiments.
We then used in vivo microdialysis to
ascertain that soluble A levels in hip-
pocampal ISF were reduced by dox treat-
ment along with transgenic APP (Fig. 2D;
Cirrito et al., 2003). Before dox treatment,
A40 levels averaged 742  106 pg/ml
(n 5) andA42 140 24 pg/ml (n 4).
The concentration of both peptides
quickly declinedwith dox treatment. Exchangeable ISFA40 and
A42 levels dropped by50%within 48 h of dox treatment (post
hoc test, p  0.001), and reached nearly 70% suppression com-
pared with baseline ISF A levels by 72 h (post hoc test, p 
0.0001). The difference between the extent of APP reduction and
that of A is likely due to the continued release of peptide from
nearby plaques even after further production is suppressed. Re-
cent work suggests that the concentration of ISF A is deter-
Figure 1. Using the tet-off system to initiate APP/A overexpression in the adult and therapeutically suppress it after amyloid
onset.A, Under normal conditions, TTAbinds to its recognition sequence in the hybrid tetO/CMVpromoter to activate transcription
of thedownstreamtransgene (APPswe/ind).Uponbindingdox, TTAundergoesa conformational switch thatpreventsDNAbinding
and stops further transcription of transgenicmRNA.B, The tet-off APPmodel uses the CaMKII promoter to control the expression
of TTA, thereby limiting transgenic APP to the forebrain. Under normal conditions, expression from this promoter begins during
late embryogenesis and transgenic APP is present at high levels by birth. In the current experiments, dox was used to delay
transgene expression until adulthood (P41–P43). Transgenic APP expressionwas initiated at 6weeks of age by removingdox from
the diet, and remained active for the next 6months. Therapeutic intervention to suppress further transgene expressionwith dox or
prevent A release with GSI began at 7.5 months of age. One cohort of dox-treated mice was harvested after just 2 weeks of
treatment toestablish theamyloid loadpresent at theoutset of behavioral testing. Behavioral testing in the remainingdox-treated
animals continued for another 3 weeks; afterward all mice were harvested for histology and biochemical analysis.
Figure 2. Dox treatment induces rapid, persistent suppression of transgenic APP and a concomitant decrease in ISF A con-
centration. A, Western blot showing APP suppression in APP/TTAmice following 1–4 d of dox treatment. Anti-A antibody 6E10
was used to detect transgenic APP in cortical homogenates. GAPDH was probed as an internal control. B, Quantification of the
immunoblot shown inA reveals that transgenic APP levels are reduced by 40%within 1 d of dox treatment and by 90%within 2 d.
C, Immunoblot analysis of transgenic APP in cortical homogenates from behaviorally tested mice demonstrates that transgene
suppression was maintained at90% throughout cognitive testing (n 5 per condition). D, Microdialysis of hippocampal ISF
reveals that following a 1 d delay, A concentration dropped at approximately the same rate and to a similar extent as transgenic
APP. The concentration of both A40 (blue; n 5) and A42 (red; n 4)were decreased by50%within 2 d of dox treatment
and 70% by 3 d.
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mined by a combination of existing
peptide in exchange with insoluble aggre-
gates and de novo synthesis (Hong et al.,
2011; Takeda et al., 2013). Consistent with
this explanation, when the reduction of
A was tested in young, predeposit ani-
mals from a line similar to the one studied
here, both transgenic APP and PBS-
soluble A42 dropped by 95% after
transgene suppression (Jankowsky et al.,
2005). Thus, dox treatment may be
equally effective at reducing new A syn-
thesis as transgenic APP, but the impact
on ISF A is likely offset by peptide shed-
ding from pre-existing aggregates. In this
regard, the outcomeof transgene suppres-
sion is precisely what has been demon-
strated in noncontrollable models using
pharmacologic secretase inhibitors (Hong
et al., 2011).
Although transgenic APP and ISF A
levels quickly declined with dox treat-
ment, our past work with this system has
shown that suppressing APP expression
halts amyloid growth without plaque
clearance (Jankowsky et al., 2005;Wang et
al., 2011). Given this, we predicted that
dox-treated animals would approxi-
mately maintain the same amyloid bur-
den as age-matched untreated controls, at
least for short periods of time. We con-
firmed that the area of total amyloid
detected by silver staining or A immu-
nohistochemistry (fibrillar	 diffuse; Fig.
3A,B), and specifically that of fibrillar amyloid detected by
thioflavine-S staining (Fig. 3C), was identical in dox-treated and
untreated mice following 2 weeks of differential treatment (p
0.05 for both cortex and hippocampus; Fig. 3D). We then de-
signed our behavioral experiments based on this time frame so
that the two groups began testing with identical plaque burden.
Over the next 3 weeks of differential treatment, fibrillar amyloid
remained unchanged in both cortex and hippocampus and was
indistinguishable between treatment groups at the end of behav-
ioral testing (two-way ANOVA, main effect of treatment, F(1,26)
 0.653,main effect of time, F(1,26) 0.004, both p 0.05). Total
amyloid load detected by A immunostaining increased more
noticeably between 2 and 5 weeks of differential treatment due to
accumulation of diffuse deposits in untreatedmice.We have pre-
viously shown that amyloid deposition in tet-off APPmice occurs
rapidly at this stage of pathology, and the significant rise observed
here over just a few weeks is not unexpected (Rodgers et al.,
2012). At the conclusion of behavioral testing, the area of A
immunostaining was significantly higher in untreated mice than
in dox-treated mice for both cortex and hippocampus (two-way
ANOVA, treatment time interaction, F(1,26) 18.49, p 0.05,
Bonferroni post hoc test, p 0.001 for cortex at 5weeks and F(1,26)
 8.44, p 0.05, Bonferroni post hoc test, p 0.01 for hippocam-
pus at 5 weeks). Thus, our findings suggest that the two groups
began behavioral testing with identical amounts of fibrillar and
total amyloid. Growth of diffuse plaques in untreated animals
lead to an increase in total amyloid during this time, while fibrillar
amyloid remained stable throughout behavioral testing in both dox-
treated and untreated animals such that they ended the experiments
with the same amount as they started.
Acquisition of spatial reference memory is restored by short-
term suppression of transgenic APP
Our initial experiments demonstrated that 2 weeks of dox treat-
ment allowed us to selectively lower ISF A levels while leaving
deposited amyloid unchanged. We took advantage of this situa-
tion to test whether acute reduction of soluble A was sufficient
to normalize behavioral impairments in plaque-bearing animals.
Behavioral analysis began with an assessment of open-field
activity to ensure that the APP/TTA mice did not display the
locomotor hyperactivity described previously with this line
(Rodgers et al., 2012). Open-field activity revealed no difference
in total distance traveled (F(5,51) 1.025, p 0.413) or in loco-
motor speed between genotypes or treatment groups (F(5,51) 
0.66, p  0.66), indicating that the APP/TTA mice used for this
study were not hyperactive compared with their TTA and non-
transgenic (NTG) siblings.
Having established that hyperlocomotion would not con-
found our behavior testing, we proceeded with a battery of cog-
nitive tests designed to examine acquisition and recall of
reference, working, and associative memory through a modified
MWM, six-armRAWM, and CFC, respectively.Wemodified the
standard MWM to both improve our sensitivity for subtle per-
formance differences, and to ensure that we could use the same
room for subsequent RAWM training. We used a train-to-
criteria version of the MWM, in which short-term memory
probes at the end of each day of training were used to assess
Figure3. Amyloid load is identicalbetweentreatmentgroupsat thestartofbehavioral testingandremainsstablewithdoxtreatment.
Silverstaining(A),anti-A immunohistochemistry(B),andthioflavine-Sstaining(C)wereusedtoassessamyloidburdenofthecortexand
hippocampus of APP/TTA transgenicmice harvested before or after behavioral testing, following 2weeks (2week, left;n 8 untreated,
n4dox)or5weeksofdifferentialtreatment,respectively(5week,right;n8untreated,n10dox).D,A immunostainingwasused
tomeasure total amyloid burden as a percentage of surface area in the cortex and hippocampus. In both regions, amyloid load remained
steady during behavioral testing in dox-treatedmice, but increased in untreated animals. The two treatment groups had similar amyloid
loads at the start of testing, but were significantly different by the end (***p 0.001). E, Thioflavine-S staining was used to measure
fibrillaramyloid in thecortexandhippocampus.Theareaof thioflavine-S stainingwas identicalbetweengroupsbeforebehavioral testing,
and remainedunchanged over the 3weeks of behavioral testing.
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spatial learning and decide if mice would proceed to a long-term
probe trial or to additional training the following day. As illus-
trated below, this approach brought all of the mice to the same
level of performance before they began RAWM testing. This al-
lowed us to examine long-term memory independent from the
rate of acquisition, and yielded days-to-criteria as an addedmea-
sure of spatial learning.
Untreated APP/TTA mice demonstrated a clear impairment
in acquisition of the MWM, swimming farther to locate the hid-
den platform during days 2 and 3 of training than either NTG or
TTA controls (F(2,102) 9.98, p 0.001; post hoc, p 0.001 for
NTG and p  0.01 for TTA; all F values are from two-way
RM-ANOVA including dox-treated groups discussed below; Fig.
4A, left). Short-termmemory, examined by probe trials at the end
of each training day, was also impaired in the untreatedAPP/TTA
mice (Fig. 4B, left). APP/TTA mice swam significantly farther
from the target zone during probe trials than either control group
(F(2,51)  39.86, p  0.001). Analysis of short-term memory by
the more common measure of percentage path in the trained
quadrant was consistent with proximity: performance of all ge-
notypes improved with training (F(2,102) 20.70, p 0.001) but
APP/TTAmice learnedmore slowly thanNTG and TTA controls
(F(2,51)  13.67, p  0.001), and by day 3 spent a significantly
smaller fraction of their swim path in the correct quadrant than
controls (NTG: p 0.001; TTA: p 0.01). Several of the control
mice reached criteria performance on day 3 and were removed
from further training, therefore comparisons of path length and
proximity were limited to days 1–3 when
all animals could be evaluated. None of
the APP/TTA mice (or 11 of 20 controls)
had reached criteria performance by this
time, and so continued training and test-
ing until they did (Fig. 4D, top). APP/TTA
mice required significantly more days of
training to reach criteria performance
than either TTA or NTG littermates
(F(2,51)  16.17, p  0.001, both p 
0.001; Fig. 4E). As each mouse reached
criteria levels, they received one final
probe trial 24 h later to assess long-term
memory and then were retired from fur-
ther training until all of the mice com-
pleted training (Fig. 4C). Although
APP/TTA mice required more days to
reach criteria, once they acquired the
task their long-term memory for the
platform location was as precise as their
NTG and TTA siblings (F(2,51)  1.25,
p  0.05).
Alongside these untreatedmice, we ex-
amined a replicate cohort of APP/TTA,
TTA, and NTG mice that received dox in
their drinking water for 2 weeks before
testing. During training, the average path
length of dox-treated APP/TTA mice was
no different from TTA or NTG controls
(p 0.05), indicating that transgene sup-
pression restored the performance of
APP/TTA mice to that of controls (Fig.
4A, right). Additionally, proximity to the
trained target during probe trials was sim-
ilar among genotypes, indicating that dox
treatment reversed short-term memory
impairment in the APP/TTA mice (p  0.05; Fig. 4B, right).
Dox-treated APP/TTA mice took the same number of days to
reach criteria performance as TTA and NTG controls (both p
0.05; Fig. 4D, bottom; E). Although transgene suppression
brought the performance of APP/TTA mice to the level of simi-
larly treated controls, the effect was not sufficient to distinguish
them from untreated APP/TTAmice (p 0.05). Behavioral res-
cue in this task was thus substantial, but not complete. A final
analysis of long-termmemory confirmed that all groups recalled
the platform location equally well, and were identical to un-
treated animals (Fig. 4C). These findings indicate that transgene
suppression partially reversed impairments in spatial reference
learning and short-term memory apparent in untreated APP/
TTA mice of the same age.
Suppression of transgenic APP rescues working memory
deficits in RAWM and associative memory impairment in
CFC
Animals next began RAWM training, consisting of eight trials
over a single training day. This task allowed us to test working
memory errors, which were scored as repeated visits to an incor-
rect arm. Untreated APP/TTA mice made significantly more er-
rors during RAWM training than either NTG or TTA controls
(F(2,52) 5.15, p 0.05, post hoc, p 0.01 and p 0.05, respec-
tively; Fig. 5A). Dox treatment completely rescued this working
memory deficit. Not only did dox-treated APP/TTA mice make
fewer errors than untreated APP/TTA mice (p  0.01; Fig.
Figure4. Acute suppression of APP/A results in partial recovery of spatial referencememory.A, Average path length required
to reach the hidden platform on the first 3 d of MWM testing. Untreated APP/TTAmice (n 10) perform significantly worse than
NTG (n 9; **p 0.01) and TTA controls (n 10; **p 0.01) on days 2 and 3 of training (left). Transgene suppressionwith dox
restored the performance of APP/TTAmice (n 9) to that of NTG (n 10) and TTA controls (n 9; right).B, Short-termmemory
(STM) probe trials were used to assess immediate recall at the end of each day. STM of untreated APP/TTA mice was worse than
controls on the first 3 d of training ( p 0.01 for day 1 and p 0.001 for days 2 and 3, left). Acute transgene suppressionwith dox
improved immediate recall in APP/TTA mice to that of controls (right). C, Twenty-four hours after mice reached criteria perfor-
mance, they were administered one final probe trial to assess long-term memory (LTM). Once all mice reached criterion perfor-
mance, their long-term recall was identical across groups. Left, Shows percentage path in the trained quadrant; right shows
proximity to target.D, Average path length required to reach the hidden platform reflects the number of training days required to
reach criteria performance for untreated (top) and dox-treated mice (bottom). E, Untreated APP/TTA mice require more days to
reach criterion thanNTG ( p 0.0001) and TTA controls ( p 0.001). Following transgene suppression, all groups reached criteria
performance in the same number of days.
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5A,B), they performed aswell as their dox-treated siblings (F(1,52)
 5.68, p 0.05; post hoc, p 0.05 for both NTG and TTA).
Two days after completing RAWM,mice were trained in CFC
and tested 24 h later in the same setting. Baseline freezing before
conditioning was similar between genotypes and treatment
groups (F(2,51)  0.41, p  0.67). However, when they were re-
turned to the chamber 1 d after conditioning, untreated APP/
TTA mice spent significantly less time freezing than NTG and
TTA littermates (F(2,51)  3.26, p  0.05; Fig. 5C). In contrast,
dox-treated APP/TTAmice showed clear improvement, freezing
significantly more than untreated APP/TTAmice (F(2,51) 5.69,
p 0.01, post hoc, p 0.05; Fig. 5D) and similar to controls (p
0.05 for both; Fig. 5C). Transgene suppression thus resulted in
complete behavioral rescue of working and associative memory
in RAWM and CFC alongside partial rescue of spatial reference
learning in MWM.
Suppression of A accounts for a portion of
behavioral recovery
Because our system regulates A through the expression of trans-
genic APP, it is impossible to distinguish whether behavioral
recovery following dox treatment was due to diminished A,
full-length APP, or other processed derivatives. To address this
question, we treated a separate cohort of age-matched APP/TTA
andTTA animals with theGSI LY41175. Animals were treated for
5 d before behavioral analysis with the same test battery used
previously for dox-treated animals (Fig. 6A).
Similar to improvements we observed following dox treat-
ment, GSI-treated APP/TTA mice swam the same distance as
controls to reach the hidden platform in MWM (Fig. 6B). Both
GSI-treated groups showed similar short-term memory for the
trained location during daily probe trials at the end of each train-
ing session (F(1,16) 0.99, p 0.05; Fig. 6C). Despite swimming
similar distances during training and showing equivalent short-
term memory for the platform location, GSI-treated double
transgenicmice took slightly longer to reach criteria performance
than TTA controls (4.78 0.32 d vs 3.33 0.37 d, t 2.25, df
16, p  0.05). Nonetheless, the effect of GSI treatment in APP/
TTA mice was nearly identical to that of dox: GSI-treated mice
required 4.7  0.31 d to reach criterion compared with 4.88 
0.48 d for dox-treated mice, and both values were lower than the
6.0 0.36 d required by the untreated APP/TTA group (Fig. 6D).
Instead, themain difference betweenGSI and doxwas in the TTA
controls, where GSI-treated mice required only 3.3 d  0.5 d to
reach criterion compared with 4.0  0.47 d for dox. Finally,
GSI-treatedmice of both genotypes performed equallywell on long-
termmemory testing (t test, t 2.29, df 16, p 0.29; Fig. 6E).
We were concerned that the side effects of GSI treatment
might confound further testing in RAWM and fear conditioning
sowe conducted a second open-field test followingMWM.While
we saw no differences between genotypes for distance (F(1,32) 
0.08, p 0.78) or center ratio (t 0.27, df 16, p 0.80), both
genotypes were significantly less active during the second open-field
test than they hadbeen at the outset ofGSI treatment (F(1,32) 8.71,
p 0.001). The decline in spontaneous ambulation was accompa-
nied by hair loss and gastrointestinal changes. Although we con-
tinued behavioral testing through RAWM and CFC, the
mounting side effects of GSI treatment confounded interpreta-
tion of these later tests.
Reduction of membrane-associated A oligomers correlates
with cognitive improvement
Having demonstrated that transgene suppression restored cogni-
tive function at least in part through its effect on A production,
we next examined the possibility that clearance of specific forms
of synaptotoxic Amay be an important aspect of this response.
Using cortical homogenates from behaviorally tested animals, we
measured the relative size and abundance of putative A oligom-
ers in the extracellular-enriched and membrane-associated frac-
tions where these A assemblies are predominantly detected
(Lesne´ et al., 2006, 2008 Cheng et al., 2007). Two soluble oligo-
meric A species, putative hexamers (27 kDa) andA*56, were
present at low levels in the extracellular compartment of un-
treated APP/TTA mice (Fig. 7A). Both oligomers were substan-
tially more concentrated in the membrane-associated extracts,
where in addition to hexamers and A*56, we also detected A
dimers (Fig. 7B). Although identification of A trimers was con-
founded by a nonspecific band at the same molecular weight in
the extracellular extract and by APP C-terminal fragments (-
CTF) in the membrane-enriched fraction, we were able to con-
firm low levels of apparent A trimers in the extracellular extracts
by 6E10 IP, as reported for other APP transgenic lines ( Lesne´ et
al., 2006; Larson et al., 2012).
All putative soluble oligomeric A species in both extracellu-
lar and membrane-associated extracts were significantly reduced
in the dox-treated mice (F(1,36)  194.80, p  0.0001 for the
membrane-associated fraction and F(1,24)  243.60, p  0.0001
for extracellular fraction; Fig. 7A,B). The two most prevalent
oligomer species, 6-mer and A*56, were reduced by 79% extra-
cellular (p 0.0001) and 68%at themembrane (p 0.0001) and
by 28% extracellular (p 0.05) and 55% at the membrane (p
0.0001), respectively. Although a minor component, A dimers
were reduced by 53% in the membrane fraction (p  0.001)
Figure 5. Deficits in working and associative memory are rescued by suppression of trans-
genic APP/A. A, The average number of errors made by each genotype over trials 2– 8 of
RAWM provides a measure of overall working memory performance. Untreated APP/TTA mice
(n 10)made significantlymore repetitive arm entries (errors) than NTG (n 9; **p 0.01)
or TTA controls (n 10; *p 0.05). In contrast, APP/TTA mice treated with dox (n 9)
perform this task significantly better thanuntreatedAPP/TTAmice (**p0.01) and identically
to NTG and TTA controls (n 10 dox NTG; n 9 dox TTA).B, Average RAWM errors plotted by
trial for untreated and dox-treated APP/TTA mice. Transgene suppression markedly improved
the rate of acquisition in this task. C, Untreated APP/TTA mice (n 10) perform significantly
worse in CFC than NTG (**p 0.01) and TTA controls (*p 0.05). Dox treatment rescues this
associativememory impairment and returns APP/TTAmice (n 9) to the performance level of
control animals.D, Percentage freezing plotted byminute over the 5min test for untreated and
dox-treated APP/TTA mice. Transgene suppression significantly improved associative memory
for conditioned fear (*p 0.05).
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while the largest aggregates, protofibrils, were decreased by 42%
(p 0.0001).
Because 6E10 detects many processed fragments of APP in
addition to oligomeric A, we performed nondenaturing analy-
ses using the A11 antibody, which detects soluble nonamyloid
oligomers larger than 20 kDa (Kayed et al., 2003; Lesne´ et al.,
2006). Under these conditions, dot blots probed with A11 con-
firmed the presence of substantial oligomeric A in both extra-
cellular and membrane extracts from untreated APP/TTA
animals. Following transgene suppression, the A11 signal was
reduced by 62% in the extracellular fraction (main effect of treat-
ment F(1,12)  191.7, p  0.0001; post hoc, p  0.0001) and by
68% in the membrane fraction (p 0.01; Fig. 7D). The dot blots
were also coincubated with 6E10, which showed a quantitatively
larger decrease in signal intensity following dox treatment than in
A11 (extracellular, 81%; membrane, 71%), consistent with its
ability to detect multiple APP fragments, A11-positive and A11-
negative A oligomers, andmonomeric A. These findings indi-
cate that soluble oligomeric A species were selectively reduced
upon genetic suppression of transgenic APP while the burden of
insoluble amyloid remained unchanged.
Moreover, the extent this reduction paral-
lels the decrease in ISF A levels observed




Past work has shown that exposure to oli-
gomeric A is rapidly synaptotoxic in
vitro, which led us to test whether synaptic
markers were also reduced in untreated
APP/TTAmice as they are in several other
amyloid-bearing ADmodels (Calon et al.,
2004; Almeida et al., 2005; Zhao et al.,
2006; D’Amelio et al., 2011). Moreover,
we wanted to determine whether synaptic
recovery accompanied the decrease in oli-
gomeric A with transgene suppression,
which might support their behavioral im-
provement. We quantified the levels of
both postsynaptic PSD95 and presynaptic
synapsin Ia/b in cortical extracts from be-
haviorally tested mice (Fig. 8A–C). West-
ern blotting confirmed that untreated
APP/TTAmice have less PSD95 than TTA
controls (F(1,28)  25.80, p  0.01; Fig.
8B) as well as lower levels of synapsin
(F(1,27)  6.20, p  0.05; Fig. 8C). Dox
treatment to suppress transgenic APP in-
creased the amount of both proteins in
APP/TTA mice, but did not affect their
levels in TTA controls (F(1,28)  11.80,
p  0.002 for PSD95 and F(1,27)  3.70,
p 0.04 for synapsin).
While these changes in synapsin and
PSD95 are consistent with synapse loss
throughout the cortex of untreated APP/
TTA mice, past work has shown that the
greatest decrease in synapse density oc-
curs in the immediate vicinity of amyloid
plaques (Spires et al., 2005; Dong et al.,
2007; Spires-Jones et al., 2007; Knafo et
al., 2009; Koffie et al., 2009). Knowing that dox-treated mice
showed behavioral improvements despite the persistence of
amyloid plaques, we tested whether plaque-associated synapse
loss was rescued by lowering A production. We manually se-
lected thioflavine-positive plaques from the rostral forebrain
ranging in size from 2500–11,000m2 so that the distribution of
plaque sizes was no different between dox-treated and untreated
mice (unpaired Student’s t test, p 0.05).We thenmeasured the
area of synaptophysin immunostaining in a 0.036 mm2 region
surrounding each plaque (one field of view at 40 magnifica-
tion) to compare the density of synapses in untreated and dox-
treated APP/TTA mice (Fig. 8D). The area of synaptophysin
staining in the vicinity of fibrillar deposits wasmarkedly higher in
the dox-treated animals than in their untreated siblings (t 3.34,
p 0.01; Fig. 8E). This suggests that synaptic loss is reversible, as
were cognitive deficits, once APP and A are reduced.
We formally tested the relationship between synaptic protein
expression and the concentration of oligomeric Ameasured in
individual APP/TTA mice with or without dox treatment. We
focused on the twomost prevalent oligomeric A species, A*56
Figure 6. Selective reduction of Awith GSI largely phenocopies transgene suppression with dox. A, As in our earlier experi-
ments, dox was used to delay transgene expression until adulthood. Transgenic APP expressionwas initiated at 6 weeks of age by
removing dox from the diet, and remained active for the duration of the experiment. Therapeutic intervention to prevent A
release with GSI began at 7.5 months of age, and behavioral testing was started 5 d later. B, Average path length during MWM
training for GSI-treated APP/TTA (red) and TTAmice (green). Performance of untreated APP/TTA animals is shown for comparison
(gray; reproduced from Fig. 3). GSI-treated APP/TTA mice required fewer training days than untreated APP/TTA mice, but more
than GSI-treated TTA controls (n 9 for each genotype). C, GSI treatment improved short-termmemory (STM) of APP/TTA mice
duringdaily probe trials to the level of TTA controls.D, UntreatedAPP/TTAmice required significantlymoredaysof training to reach
criteria performance than TTA controls (**p 0.01); however, this impairment was attenuated by both dox and GSI treatment.
Data for this graph was analyzed by two-way ANOVA to allow comparison between treatment groups (F(1,50) 19.70, p
0.0001); analyses presented in the text were limited to GSI-treated groups and therefore used t test. E, All groups, regardless of
genotype or treatment, performed identically during the long-term probe trial conducted 24 h after the final training session.
Untreated and dox-treated days to criteria and long-termmemory (LTM) values are reproduced from Figure 4.
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and hexamers, measured by Western blot of extracellular and
membrane extracts (Fig. 7A), as well as A11-positive oligomers
measured by dot blot (Fig. 7C). Levels of these oligomers were
tested for correlation against expression of the presynaptic
marker synapsin measured by Western blot of intracellular ex-
tract from the same animals (Fig. 8A). Based on the general trend
for each of these proteins before and after transgene suppression,
we predicted there would be a strong negative correlation be-
tween oligomeric A concentration and synaptic protein expres-
sion. Linear regression analyses confirmed this prediction,
revealing R2 of 0.81 (extracellular) and 0.76 (membrane) for
hexamers (p 0.01 for both; Fig. 9A), R2 of 0.59 (extracellular)
and 0.73 (membrane) for A*56 (p 0.05 and p 0.01, respec-
tively; Fig. 9B), and R2 of 0.69 (extracellular) and 0.68 (mem-
brane) for A11-positive oligomers (p  0.05 for both; Fig. 9C).
Our data thus supports and extends past in vitro studies suggest-
ing a direct relationship between soluble oligomeric A and syn-
aptic integrity.
Synaptic regrowth corresponds with restored cofilin activity
While oligomeric Amay initiate synaptic collapse, the intracel-
lular mediator of structural changes at the synapse is the actin
cytoskeleton. Opposing actions of Rho- and Rac-GTPases are
critical to the balance between synapse maintenance and turn-
over, and imbalance of these pathways is associated with several
neurodegenerative conditions (Antoine-Bertrand et al., 2011;Ma
et al., 2012). Both pathways ultimately converge on the actin-
binding protein cofilin, which promotes collapse through actin
depolymerization, but only in its active, dephosphorylated form.
Past work has implicated the Rac-GTPase pathway in amyloid-
associated synaptic deficits, showing that exposure to oligomeric
Adiminishes activity of its downstreameffector PAK in primary
neurons, and conversely that oligomer-induced loss of synaptic
markers can be ameliorated by increasing PAK levels (Zhao et al.,
2006).
Western blotting of cortical intracellular homogenates re-
vealed a significant imbalance of cofilin phosphorylation in un-
Figure 7. APP suppression reduces soluble synaptotoxic A assemblies. A, A four-step biochemical fractionation was used to enrich for extracellular (top) and membrane-associated proteins
(bottom) in cortical samples from behaviorally tested mice (n 4 APP/TTA untreated, n 4 APP/TTA dox; n 2 TTA untreated, n 2 TTA dox). Immunoblotting with anti-A antibody 6E10
revealed multiple oligomeric A species in addition to full-length APP and sAPP. Putative hexamers (6-mers) and A*56 were especially prevalent in the membrane-associated fraction. The
asterisk in the upper blot indicates a band of nonspecific binding present in all samples. Additional gels were prepared with an identical volume of the same samples and probed for-synuclein
(extracellular) or actin (membrane) to demonstrate equal loading across lanes ( p 0.05 between treatment conditions for both fractions).B, Densitometry analysis revealed that both A*56 and
hexamers were significantly diminished in dox-treated APP/TTA animals compared with untreated controls. C, Dot blots were used to distinguish the signal due to oligomeric A from that caused
by other fragments of APP (n 4 APP/TTA untreated, n 4 APP/TTA dox; n 2 TTA untreated, n 2 TTA dox). Blots were coincubated with oligomer-specific A11 and with 6E10, and detected
withanti-rabbit IR680andanti-mouse IR800 secondaries, respectively.D, Signal intensity for bothA11and6E10wasdecreasedafter transgene suppression comparedwithuntreated controls; *p
0.05, ***p 0.001. A.U., arbitrary units.
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treated APP/TTA mice, which harbored more protein in the
inactive phosphorylated state than controls (F(1,12)  8.87, p 
0.01, post hoc, p  0.05; Fig. 10A). Cofilin phosphorylation was
restored to normal by transgene suppression (post hoc, p 0.05)
without affecting the total amount of cofilin protein (Fig. 10B).
Our results suggest that aberrant cofilin activation may mediate
synaptic loss in our model through a dy-
namic process that returns to normal once
APP/A subsides. Consistent with past
work (Zhao et al., 2006; Ma et al., 2008),
we observed a significant decrease of
Thr423 phosphorylation of PAK1 in dou-
ble transgenic mice (F(1,12)  96.23, p 
0.0001; Fig. 10C,D).However, pPAK1 lev-
els were not further altered by transgene
suppression. These findings suggest that
the recovery of cofilin activity after trans-
gene suppression, as well as the rescue of
synaptic proteins and cognitive behavior,
are all independent of PAK1 activity.
Discussion
One of the uncertainties surrounding new
anti-amyloid treatments for AD is
whether lowering the concentration of
soluble A will be sufficient to achieve
substantial and sustained cognitive im-
provement. Here, we set out to test the
extent of behavioral and synaptic recovery
that could be achieved by reducing soluble
A without macroscopically altering in-
soluble plaque burden. We describe sub-
stantial cognitive deficits while transgene
expression persists, but nearly complete
behavioral recovery across a wide range of
memory tasks following acute reduction
of APP and A. Cognitive improvements
correlated with restoration of synaptic
proteins, increased synaptic density sur-
rounding amyloid plaques, and normal-
ized phosphorylation of actin-binding
proteins controlling synaptic stability.
Together, these findings argue that high
levels of APP and the ensuing supply of
soluble A actively dampen synaptic con-
dition and cognitive function, but indi-
cate a striking potential for structural and
functional recovery once further produc-
tion of APP and A are controlled. Re-
markably, this recovery occurred despite
the continued presence of deposited amy-
loid and associated pathology, suggesting
the possibility for considerable therapeu-
tic benefit by targeting full-length APP
and/or soluble A to arrest plaque growth
without the need to reduce plaque
burden.
To determine whether the cognitive
improvements observed following trans-
gene suppression were mediated by the
reduction in A, we used chronic GSI
treatment to prevent A release while the
animals continued to overproduce APP.
We found that GSI improved the perfor-
mance of APP/TTA mice in the MWM, but did not offer com-
plete rescue. This outcome suggests that either our GSI did not
lower A enough for full recovery, or that A is only partly re-
sponsible for cognitive decline in our mice. Importantly, these
behavioral improvements following GSI treatment appear in
Figure 8. Synaptic protein levels and synaptic area are restored by suppression of transgenic APP/A. A, Immunoblottingwas
used tomeasure the levels of presynaptic andpostsynaptic proteins synapsin andPSD95 in cortical homogenates frombehaviorally
tested animals.B,C, The signal intensity revealed significant deficits in both synapsin andPSD95betweenuntreatedAPP/TTAmice
(n 8) and TTA controls (n 8; *p 0.05). Levels of both proteins were increased by dox treatment in APP/TTA mice (n 8;
*p 0.05) to levels that were indistinguishable from TTA controls (n 8). D, Synaptophysin immunostaining (red) was used to
estimate the area occupied by synaptic terminals in the vicinity of thioflavine-positive fibrillar plaques (green) at the conclusion of
behavioral testing. E, Consistent with the recovery of synaptic proteins, the area of synaptophysin immunostaining was signifi-
cantly greater in dox-treated APP/TTA mice than in untreated controls (**p 0.01; n 8 untreated; n 10 dox).
Figure 9. Synaptic protein expression correlates with oligomeric A levels. A, B, Graphs showing the level of synapsin protein
measured by Western blot of intracellular tissue extract as a function of the amount of A*56 (A) A hexamer (B) measured by
Western blot of extracellular (squares) ormembrane extract (circles) from the same animal. C–E, Graph showing synapsin expres-
sion as a functionofA11-positive (C) and82E1-positive (D) oligomeric AorOC-positive fibrils (E)measuredbydot blot. Values are
expressed as arbitrary units (AU). Red, n 4 untreated; blue, n 4 dox.
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sharp contrast to our recent finding that
GSI had little effect on other phenotypes
such as electroencephalographic sharp-
wave discharge that could be attenuated
by APP suppression (Born et al., 2014).
Thus, A does not contribute to every
phenotype observed in APP models, but
does appear to play a role in their cogni-
tive dysfunction. Our results join a hand-
ful of past studies to separate the effects of
APP from A using passive immuniza-
tion, -secretase and -secretase inhibi-
tors, or -secretase modulators. Although
they differ in extent of cognitive recovery,
starting plaque load, and testing proce-
dures, these studies collectively point to
soluble A as an important mediator of
cognitive decline in APP transgenic mod-
els (Dodart et al., 2002; Comery et al.,
2005; Lee et al., 2006;Martone et al., 2009;
Fukumoto et al., 2010; Balducci et al.,
2011; Chang et al., 2011; Mitani et al.,
2012, 2013; Rogers et al., 2012).
Cognitive improvements observed af-
ter transgene suppression were associated
with structural recovery at the synaptic
level. A limited number of studies in vitro
and in vivo have hinted at the possibility of
synaptic recovery following treatments to
reduce A levels, but never in the context
of sustained amyloid load (Buttini et al., 2005; Rozkalne et al.,
2009; Spires-Jones et al., 2009; Wei et al., 2010). Consistent with
past work showing diminished levels of PSD95 in cultured neu-
rons fromTg2576mice (Almeida et al., 2005), we observed loss of
both the presynaptic and postsynapticmarkers in untreatedAPP/
TTA mice. However, this deficit was fully reversible following
short-term suppression of transgenic APP. As in otherAPP trans-
genic models, we observed diminished synaptic staining sur-
rounding amyloid plaques in untreated APP/TTAmice (Dong et
al., 2007; Koffie et al., 2009; Spires-Jones and Knafo, 2012), but
demonstrate significant structural recovery following APP/A
suppression. Although the thioflavine-positive plaque load re-
mained stable, the concentration of potentially synaptotoxic oli-
gomeric A decreased significantly after APP suppression. The
amount of oligomeric A in the brain was inversely correlated
with synaptic protein levels and synaptic density. Both markers of
synaptic integrity increased significantly when oligomeric A
decreased.
Previous work with cultured neurons has suggested a mecha-
nistic link between exposure to oligomeric A and the intracel-
lular signaling pathways that regulate synapse stability. Work has
revealed roles for the PAKs and their downstream target cofilin in
spine loss following application of soluble A aggregates (Zhao et
al., 2006; Shankar et al., 2007; Davis et al., 2011; Mendoza-
Naranjo et al., 2012). The activity of both proteins is regulated by
phosphorylation, which in the case of cofilin, serves as a way to
stabilize synaptic structure by preventing F-actin disassembly
(Mizuno, 2013). We find that cofilin phosphorylation was sub-
stantially elevated in the cortex of untreated APP/TTA mice,
where it may either be a direct result of exposure to soluble
forms of A or may serve as a compensatory response to pro-
tect against further synapse loss. Consistent with the former
idea, cofilin phosphorylation was shown to increase rapidly in
primary neurons following application of aggregated A (Here-
dia et al., 2006). Supporting the latter idea, constitutively inactive
cofilin (S3D) protects neurons from spine loss during prolonged
exposure to oligomeric A (Shankar et al., 2007). Regardless of
whether the response is direct or reactive, cofilin phosphorylation
comes at the cost of structural plasticity required for learning-
associated changes in synaptic structure and function. Cofilin
phosphorylation is dynamically regulated by neuronal stimula-
tion in vitro and behavioral learning in vivo, where it participates
both in modulating synaptic size and in trafficking AMPA recep-
tors to the membrane (Saneyoshi and Hayashi, 2012). Loss of
cofilin in the forebrain impairs associative memory, while block-
ing its activation retards extinction learning (Rust et al., 2010;
Wang et al., 2013). Thus, diminished cofilin activity in untreated
APP/TTAmicemay contribute to their poor cognitive flexibility.
Once the production of transgenic APP and A was sup-
pressed, cofilin activity returned to normal and synapse density
around plaques increased. Past work identified p21-associated
kinase, PAK1, as a key mediator of oligomeric A-induced syn-
apse loss (Zhao et al., 2006). As shown for the Tg2576 model, we
too observed a dramatic reduction of PAK1 phosphorylation in
untreated APP/TTA mice. In contrast to the complete rescue of
PAK1 activity found by Zhao et al. (2006) following anti-A
antibody treatment, we found no further change in PAK1 phos-
phorylation with APP/A suppression. Although we have not
excluded the possibility for cellular redistribution of PAK1 fol-
lowing APP suppression (Ma et al., 2008), our findings suggest
that synapse recovery and cognitive improvement in our model
are independent of PAK1 signaling.
While past work linking oligomeric A to synapse loss pro-
vided a framework for interpreting our data, we cannot exclude
the possibility that other fragments of APPmay also contribute to
Figure 10. Transgene suppression restores normal cofilin activity independent of PAK1. A, Immunoblotting was used to mea-
sure phosphorylation of the actin depolymerizing protein cofilin, and its upstream regulator PAK1, in cortical homogenates from
behaviorally tested animals (n 4 per group).B, C, Quantitation of the blots shown inA revealed that cofilin phosphorylationwas
significantly increased in untreated APP/TTA mice compared with NTG controls (*p 0.05), but returned to normal following
transgene suppression. In contrast, PAK1 phosphorylation was significantly decreased in untreated APP/TTA mice relative to
controls, but remained so even after transgene suppression diminished oligomeric A levels and restored normal expression of
synaptic proteins.
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synapse loss and cognitive decline in the APP/TTA mice. Genet-
ically inhibiting the expression of full-length APP not only low-
ered A production but also reduced APP, soluble extracellular
derivatives (sAPP), and APP intracellular domain. Our system
thereby provides experimental proof of principle that modulat-
ing APP gene expression in the human brain might be therapeu-
tically beneficial. Based on these results, we propose that
antisense oligodeoxynucleotides (ASO) targeting APP mRNA
could offer ameans of loweringAwithout assuming it is the sole
causal agent. ASO therapy has the added advantage of being di-
rectly translatable to clinical trials, and is currently in testing for
both spinal muscular atrophy and amyotrophic lateral sclerosis
(www.Clinicaltrials.gov ID NCT01839656; Miller et al., 2013).
Although considerable effort has focused on selectively lowering
A, our study shows that targeting full-length APP may offer
another means of accomplishing this goal.
Collectively, our results point to transient assemblies of A as
the most likely cause of synaptic and cognitive deficits in our
APP/TTAmice.We demonstrate substantial structural and func-
tional improvements following short-term suppression of trans-
genic APP and the subsequent reduction of monomeric and
oligomeric A, despite the continued presence of fibrillar amy-
loid deposits. We further show that aberrant cofilin phosphory-
lation corresponds with synaptic loss in untreated APP/TTA
mice, and that cofilin activity and synaptic integrity are restored
to normal following arrest of transgenic APP and A. Future
studies will need to address whether this benefit can be main-
tained long term, and if the same degree of recovery observed
here can be achieved at later stages of disease when amyloid load
increases exponentially (Kawarabayashi et al., 2001; Rodgers et
al., 2012) and cognitive impairment becomes progressively worse
(Westerman et al., 2002; Trinchese et al., 2004). Nonetheless, at
least at this early stage of disease, our findings support the possi-
bility for considerable functional and structural recovery by ge-
netically targeting transient forms of soluble A.
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